MITAC-COMPUTING
16.11.2021 16:02:10 CET | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, features a range of HPC and AI server platforms powered by 3rd Gen Intel® Xeon® Scalable processors, which are optimized for enterprises and data centers, at SC21 virtual event through November 18th .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005013/en/
“With advances in cloud computing, IoT adoption, and 5G, data is increasingly generated everywhere, by everything, and therefore data-fueled organizations need a powerful foundation that can keep pace with changing markets and their competitors,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN HPC and AI platforms give enterprises the right foundation of scalability and performance to build their data centers.”
Accelerate Performance for HPC and AI
Powered by 3rd Gen Intel Xeon Scalable processors, TYAN’s HPC and AI platforms are designed to accelerate performance for a wide range of compute-intensive workloads, including high performance computing, deep learning, and virtualization applications. The Thunder HX TS75-B7122 is a 2U system designed for AI inference and in-memory computing workloads, supporting dual 3rd Gen Intel Xeon Scalable processors, 32 DDR4 DIMM slots, two PCIe 4.0 x16 slots for double-width, active-cooled GPUs, and twelve 3.5-inch tool-less SATA drive bays with up to four NVMe U.2 support.
The Thunder HX FT65T-B5642 is a 4U single-socket pedestal server built for smaller HPC workloads that need large computing power at the deskside. The system features a single 3rd Gen Intel Xeon Scalable processor, eight DDR4-3200 DIMM slots, eight 3.5-inch SATA, and two NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B5642 supports two double-width PCIe 4.0 x16 slots for GPUs to accelerate HPC applications.
TYAN's Thunder HX FT83A-B7129 is a 4U dual-socket supercomputer supporting up to ten high-performance GPU cards. Powered by dual 3rd Gen Intel Xeon Scalable processors and 32 DDR4 DIMMs, the FT83A-B7129 platform provides outstanding heterogeneous computing power for a variety of GPU-based scientific high performance computing, AI training, inference, and deep learning applications. The system offers twelve 3.5-inch tool-less drive bays with up to four NVMe U.2 devices support.
Moreover, the Tempest HX S7120 is a mainstream server motherboard in SSI EEB (12" x 13.1") form factor, and the Tempest HX S5642 is a standard server motherboard in SSI CEB (12" x 10.6") form factor. The S7120 supports dual processors, 16 DDR4-3200 DIMM slots, dual 10GbE or GbE onboard network connections, three PCIe 4.0 x16 and two NVMe M.2 slots. The S5642 is equipped with a single processor socket, eight DDR4-3200 DIMM slots, two 10GbE and one GbE LAN ports, three PCIe 4.0 x16 and two NVMe M.2 slots.
Supporting Resources:
Please watch this video about TYAN 3rd Gen Intel Xeon Scalable processor servers designed to accelerate performance for HPC and AI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
